BN.com Gift Guide

Cancer Bioinformatics - From Therapy Design to Treatment / Edition 1

Hardcover (Print)
Buy New
Buy New from BN.com
$137.78
Used and New from Other Sellers
Used and New from Other Sellers
from $96.30
Usually ships in 1-2 business days
(Save 41%)
Other sellers (Hardcover)
  • All (6) from $96.30   
  • New (4) from $127.34   
  • Used (2) from $96.30   

Overview

"The development and application of bioinformatics tools to basic and translational cancer research is, in fact, a rapidly expanding field that deserves a timely review. Therefore, a publication of this type is needed. The editors have done an excellent job in recruiting well-established scientists to author the various chapters of the book."
Dieter Naf, Jackson Laboratory, USA

Cancer bioinformatics is now emerging as a new interdisciplinary field, which is facilitating an unprecedented synthesis of knowledge arising from the life and clinical sciences.

This groundbreaking title provides a comprehensive and up-to-date account of the enormous range of bioinformatics for cancer therapy development from the laboratory to clinical trials. It functions as a guide to integrated data exploitation and synergistic knowledge discovery, and support the consolidation of the interdisciplinary research community involved.

Read More Show Less

Editorial Reviews

From the Publisher
"…recommended for purchase for medical, academic or special libraries serving basic or clinical cancer researchers and bioinformaticists." (E-STREAMS, September 2007)

"…good reading for anyone entering into some aspect of cancer research, whether it is biological, mathematical, or computational…" (Biometrics, December 2006)

"Overall … an excellent and well-edited book that could be read from cover to cover or used as a reference." (British Journal of Healthcare Computing and Information Management, July 2006)

Read More Show Less

Product Details

  • ISBN-13: 9780470863046
  • Publisher: Wiley
  • Publication date: 3/24/2006
  • Edition number: 1
  • Pages: 300
  • Product dimensions: 6.83 (w) x 9.72 (h) x 0.94 (d)

Meet the Author

Dr Sylvia Nagl, Senior Lecturer, Department of Oncology, University College, London

Read More Show Less

Table of Contents

Preface.

List of Contributors.

SECTION I CANCER SYSTEMS.

1 A Path to Knowledge: from Data to Complex Systems Models of Cancer (Sylvia Nagl).

1.1 Conceptual foundations: biological complexity.

1.2 A taxonomy of cancer complexity.

1.3 Modelling and simulation of cancer systems.

1.4 Data standards and integration.

1.5 Concluding remarks.

2 Theory of Cancer Robustness (Hiroaki Kitano).

2.1 Robustness: the fundamental organizational principle of biological systems.

2.2 Underlying mechanisms for robustness.

2.3 Intrinsic features of robust systems: evolvability and trade-offs.

2.4 Cancer as a robust system.

2.5 Therapy strategies.

2.6 A proper index of treatment efficacy.

2.7 Computational tools.

2.8 Conclusion.

3 Developing an Integrated Informatics Platform for Cancer Research (Richard Begent).

3.1 Background.

3.2 The challenge.

3.3 The UK National Cancer Research Institute (NCRI) informatics platform.

3.4 Developing the informatics platform.

3.5 Benefits of the platform.

3.6 Conclusions.

SECTION II In silico MODELS.

4 Mathematical Models of Cancer (Manish Patel and Sylvia Nagl).

4.1 Growth models.

4.2 A very brief tour of cellular automata.

4.3 Angiogenesis models.

4.4 Treatment response models.

4.5 Dynamic pathways models.

4.6 Other models.

4.7 Simulations of complex biological systems.

4.8 Concluding remarks.

5 Some Mathematical Modelling Challenges and Approaches in Cancer (Philip Maini and Robert A. Gatenby).

5.1 Introduction.

5.2 Multiscale modelling.

5.3 Tumour vascular modelling.

5.4 Population models.

5.5 Conclusion.

6 Computer Simulation of Tumour Response to Therapy (Georgios S. Stamatakos and Nikolaos Uzunoglu).

6.1 Introduction.

6.2 Tumour growth simulation.

6.3 Radiotherapy response simulation.

6.4 Chemotherapy response simulation.

6.5 Simulation of tumour response to other therapeutic modalities.

6.6 Simulation of normal tissue response to antineoplastic interventions.

6.7 Integration of molecular networks into tumour behaviour simulations.

6.8 Future directions.

7 Structural Bioinformatics in Cancer (Stephen Neidle).

7.1 Introduction.

7.2 Macromolecular crystallography.

7.3 Molecular modelling.

7.4 Conclusions.

SECTION III In vivo MODELS.

8 The Mouse Tumour Biology Database: an Online Resource for Mouse Models of Human Cancer (Carol J. Bult, Debra M. Krupke, Matthew J. Vincent, Theresa Allio, John P. Sundberg, Igor Mikaelian and Janan T. Eppig).

8.1 Introduction.

8.2 Background.

8.3 Database content.

8.4 Data acquisition.

8.5 Using the MTB database.

8.6 Connecting the MTB database with related databases.

8.7 Summary.

9 Bioinformatics Approaches to Integrate Cancer Models and Human Cancer Research (Cheryl L. Marks and Sue Dubman).

9.1 Background.

9.2 The MMHCC Informatics at the outset of the programme.

9.3 Initial NCI bioinformatics infrastructure development.

9.4 Future directions for informatics support.

9.5 Summary.

SECTION IV DATA.

10 The FAPESP/LICR Human Cancer Genome Project: Perspectives on Integration (Ricardo Brentani, Anamaria A. Camargo, Helena Brentani and Sandro J. De Souza).

10.1 Introduction.

10.2 The FAPESP/LICR Human Cancer Genome Project.

10.3 An integrated view of the tumour transcriptome.

10.4 Summary.

11 Today’s Science, Tomorrow’s Patient: the Pivotal Role of Tissue, Clinical Data and Informatics in Modern Drug Development (Kirstine Knox, Amanda Taylor and David J. Kerr).

11.1 Introduction.

11.2 A new national strategy for the provision of tissue annotated with clinical information to meet current and future needs of academic researchers and industry.

11.3 The NCRI National Cancer Tissue Resource for cancer biology and treatment development.

11.4 A potential future world-class resource integrating research and health service information systems and bioinformatics for cancer diagnosis and treatment.

11.5 A proposed information system architecture that will meet the challenges and deliver the required functionality: an overview.

11.6 Consent and confidentiality: ensuring that the NCTR is embedded in the UK’s legal and ethical framework.

11.7 Concluding remarks: future challenges and opportunities.

SECTION V ETHICS.

12 Software Design Ethics for Biomedicine (Don Gotterbarn and Simon Rogerson).

12.1 The problem: software and research.

12.2 Risk identification.

12.3 Biomedical software example.

12.4 Is an ethical risk analysis required?

12.5 Details of SoDIS.

12.6 A SoDIS analysis of the biomedical software example.

12.7 Conclusion.

13 Ethical Issues of Electronic Patient Data and Informatics in Clinical Trial Settings (Dipak Kalra and David Ingram).

13.1 Introduction.

13.2 Ethical aspects of using patient-identifiable health data.

13.3 Legislation and policies pertaining to patient-identifiable health data.

13.4 Using anonymized and pseudonymized data.

13.5 Protecting personal health data.

14 Pharmacogenomics and Cancer: Ethical, Legal and Social Issues (Mary Anderlik Majumder and Mark Rothstein).

14.1 Introduction.

14.2 Getting pharmacogenomic tests and drugs to market.

14.3 Cost and coverage issues.

14.4 Ethical challenges of pharmacogenomics.

14.5 Conclusion.

Index

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)